Cervantes-Villagrana RD, Cervantes-Villagrana AR, Presno-Bernal JM

Idioma: Español
Referencias bibliográficas: 57
Paginas: 440-449
Archivo PDF: 516.40 Kb.

RESUMEN

La inflamación es un proceso fisiológico que permite erradicar un agente patógeno y reparar el tejido lesionado. Es controlada y culminada mediante mecanismos de retroalimentación negativa que permiten restablecer la homeostasis del organismo; pero si la inflamación persiste, genera un proceso deletéreo en enfermedades autoinmunes o puede contribuir a enfermedades como la obesidad y el cáncer. La resolución de la inflamación consiste en la participación de fenómenos fisiológicos que involucran la disminución de la proliferación y maduración de células inmunes, así como en la inducción de la apoptosis y fagocitosis de leucocitos activos, y en la inhibición de la secreción de mediadores inflamatorios y la depuración de los mismos. En este sentido, es plausible orientar la terapéutica para aprovechar los efectos fisiológicos de los receptores que participan específicamente en la resolución de la inflamación mediante agonistas específicos, ya que la terapéutica convencional orientada a la inhibición de mediadores proinflamatorios presenta desventajas a causa de la alteración de otros procesos fisiológicos. En este trabajo se revisan algunos mecanismos asociados con el control de la inflamación y que por ello son objeto de investigación, particularmente los receptores que participan en la transducción de señales y que son relevantes por su potencial terapéutico.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Chen M, Wang J. Programmed cell death of dendritic cells in immune regulation. Immunol Rev. 2010;236:11-27.

2. Abbas AK, Lichtman AH, Pillai S. Cellular and molecular immunology. Filadelfia: Saunders Elsevier; 2007.

3. Serhan CN. Novel lipid mediators and resolution mechanisms in acute inflammation: to resolve or not? Am J Pathol. 2010;177(4):1576-91.

4. Shik D, Munitz A. Regulation of allergic inflammatory responses by inhibitory receptors. Clin Exp Allergy. 2010;40(5):700-9.

5. Chen GY, Nunez G. Sterile inflammation: sensing and reacting to damage. Nat Rev Immunol. 2010;10(12):826-37.

6. Nathan C. Points of control in inflammation. Nature. 2002;420(6917): 846-52.

7. Janssen WJ, Henson PM. Cellular regulation of the inflammatory response. Toxicol Pathol. 2012;40(2):166-73.

8. Bannenberg G, Serhan CN. Specialized pro-resolving lipid mediators in the inflammatory response: An update. Biochim Biophys Acta. 2010;1801 (12):1260-73.

9. Trivedi SG, Newson J, Rajakariar R, et al. Essential role for hematopoietic prostaglandin D2 synthase in the control of delayed type hypersensitivity. Proc Natl Acad Sci U S A. 2006;103(13):5179-84.

10. Gilroy DW. Eicosanoids and the endogenous control of acute inflammatory resolution. Int J Biochem Cell Biol. 2010;42(4):524-8.

11. Levy BD, Clish CB, Schmidt B, Gronert K, Serhan CN. Lipid mediator class switching during acute inflammation: signals in resolution. Nat Immunol. 2001;2(7)612-9.

12. Claria J, Serhan CN. Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. Proc Natl Acad Sci U S A. 1995;92(21):9475-9.

13. Serhan CN, Chiang N. Endogenous pro-resolving and anti-inflammatory lipid mediators: a new pharmacologic genus. Br J Pharmacol. 2008;153 Suppl 1;S200-15.

14. Bannenberg GL. Therapeutic applicability of anti-inflammatory and proresolving polyunsaturated fatty acid-derived lipid mediators. Scientific- WorldJournal. 2010;10:676-712.

15. Perretti M, Chiang N, La M, et al. Endogenous lipid- and peptide-derived anti-inflammatory pathways generated with glucocorticoid and aspirin treatment activate the lipoxin A4 receptor. Nat Med. 2002;8(11):1296-302.

16. Hutchinson SA, Baker SP, Scammells PJ. New 2,N6-disubstituted adenosines: potent and selective A1 adenosine receptor agonists. Bioorg Med Chem. 2002;10(4):1115-22.

17. Getting SJ, Christian HC, Lam CW, et al. Redundancy of a functional melanocortin 1 receptor in the anti-inflammatory actions of melanocortin peptides: studies in the recessive yellow (e/e) mouse suggest an important role for melanocortin 3 receptor. J Immunol. 2003;170(6):3323-30.

18. Clark RL, Johnston BF, Mackay SP, et al. The drug discovery portal: a computational platform for identifying drug leads from academia. Curr Pharm Des. 2010;16(15):1697-702.

19. Dufton N, Hannon R, Brancaleone V, et al. Anti-inflammatory role of the murine formyl-peptide receptor 2: ligand-specific effects on leukocyte responses and experimental inflammation. J Immunol. 2010;184(5):2611-9.

20. Serhan CN. Controlling the resolution of acute inflammation: a new genus of dual anti-inflammatory and proresolving mediators. J Periodontol. 2008;79(8 Suppl):1520-6.

21. Serhan CN, Hong S, Lu Y. Lipid mediator informatics-lipidomics: novel pathways in mapping resolution. AAPS J. 2006;8(2):E284-97.

22. Serhan CN. Systems approach with inflammatory exudates uncovers novel anti-inflammatory and pro-resolving mediators. Prostaglandins Leukot Essent Fatty Acids. 2008;79(3-5):157-63.

23. Adhikary S, Kocieda VP, Yen JH, Tuma RF, Ganea D. Signaling through cannabinoid receptor 2 suppresses murine dendritic cell migration by inhibiting matrix metalloproteinase 9 expression. Blood. 2012;120(18): 3741-9.

24. Klein TW, Newton C, Zhu W, Daaka Y, Friedman H. delta 9-Tetrahydrocannabinol, cytokines, and immunity to Legionella pneumophila. Proc Soc Exp Biol Med. 1995;209(3):205-12.

25. Bouaboula M, Rinaldi M, Carayon P, et al. Cannabinoid-receptor expression in human leukocytes. Eur J Biochem. 1993;214(1):173-80.

26. Galiegue S, Mary S, Marchand J, et al. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem. 1995;232(1):54-61.

27. Waldo JP, Zhang X, Shi F, Larock RC. Efficient synthesis of fluoren- 9-ones by the palladium-catalyzed annulation of arynes by 2-haloarenecarboxaldehydes. J Org Chem. 2008;73(17):6679-85.

28. Zuardi AW. Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action. Rev Bras Psiquiatr. 2008;30(3):271-80.

29. Zhu LX, Sharma S, Stolina M, et al. Delta-9-tetrahydrocannabinol inhibits antitumor immunity by a CB2 receptor-mediated, cytokine-dependent pathway. J Immunol. 2000;165(1):373-80.

30. Waldburger JM, Firestein GS. Regulation of peripheral inflammation by the central nervous system. Curr Rheumatol Rep. 2010;12(5):370-8.

31. Steinman L. Elaborate interactions between the immune and nervous systems. Nat Immunol. 2004;5(6):575-81.

32. Tracey KJ. Physiology and immunology of the cholinergic antiinflammatory pathway. J Clin Invest. 2007;117(2):289-96.

33. Li J, Mathieu SL, Harris R, et al. Role of alpha7 nicotinic acetylcholine receptors in regulating tumor necrosis factor-α (TNF-α) as revealed by subtype selective agonists. J Neuroimmunol. 2011;239(1-2):37-43.

34. Sun L, Zhang GF, Zhang X, et al. Combined administration of anisodamine and neostigmine produces anti-shock effects: involvement of alpha7 nicotinic acetylcholine receptors. Acta Pharmacol Sin. 2012;33(6): 761-6.

35. Wang H, Yu M, Ochani M, et al. Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature. 2003;421 (6921):384-8.

36. Borovikova LV, Ivanova S, Nardi D, et al. Role of vagus nerve signaling in CNI-1493-mediated suppression of acute inflammation. Auton Neurosci. 2000;85(1-3):141-7.

37. Straub RH, Wiest R, Strauch UG, Harle P, Scholmerich J. The role of the sympathetic nervous system in intestinal inflammation. Gut. 2006; 55(11):1640-9.

38. Quintana A, Muller M, Frausto RF, et al. Site-specific production of IL-6 in the central nervous system retargets and enhances the inflammatory response in experimental autoimmune encephalomyelitis. J Immunol. 2009;183(3):2079-88.

39. Gosain A, Williams RF, Blakely ML. Distinguishing acute from ruptured appendicitis preoperatively in the pediatric patient. Adv Surg. 2010; 44:73-85.

40. Jiang Q, Bai T, Shen S, Li L, Ding H, Wang P. Increase of cytosolic calcium induced by trichosanthin suppresses cAMP/PKC levels through the inhibition of adenylyl cyclase activity in HeLa cells. Mol Biol Rep. 2011;38(4):2863-8.

41. Li FC, Chan JY, Chan SH, Chang AY. In the rostral ventrolateral medulla, the 70-kDa heat shock protein (HSP70), but not HSP90, confers neuroprotection against fatal endotoxemia via augmentation of nitricoxide synthase I (NOS I)/protein kinase G signaling pathway and inhibition of NOS II/peroxynitrite cascade. Mol Pharmacol. 2005;68(1):179-92.

42. Roncarolo MG, Gregori S, Battaglia M, Bacchetta R, Fleischhauer K, Levings MK. Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol Rev. 2006;212:28-50.

43. Namba K, Kitaichi N, Nishida T, Taylor AW. Induction of regulatory T cells by the immunomodulating cytokines alpha-melanocyte-stimulating hormone and transforming growth factor-beta2. J Leukoc Biol. 2002; 72(5):946-52.

44. Lechner MG, Liebertz DJ, Epstein AL. Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells. J Immunol. 2010;185(4):2273-84.

45. El Kasmi KC, Holst J, Coffre M, et al. General nature of the STAT3-activated anti-inflammatory response. J Immunol. 2006;177(11):7880-8.

46. Zakrzewicz A, Kouri FM, Nejman B, et al. The transforming growth factorbeta/ Smad2,3 signalling axis is impaired in experimental pulmonary hypertension. Eur Respir J. 2007;29(6):1094-104.

47. Wigginton SJ, Furtado PB, Armour KL, et al. An immunoglobulin E-reactive chimeric human immunoglobulin G1 anti-idiotype inhibits basophil degranulation through cross-linking of FcepsilonRI with FcgammaRIIb. Clin Exp Allergy. 2008;38(2):313-9.

48. Blank U, Rivera J. The ins and outs of IgE-dependent mast-cell exocytosis. Trends Immunol. 2004;25(5):266-73.

49. Metcalfe DD, Peavy RD, Gilfillan AM. Mechanisms of mast cell signaling in anaphylaxis. J Allergy Clin Immunol. 2009;124(4):639-46; quiz 47-8.

50. Bischoff SC. Role of mast cells in allergic and non-allergic immune responses: comparison of human and murine data. Nat Rev Immunol. 2007;7(2):93-104.

51. Kageyama-Yahara N, Suehiro Y, Yamamoto T, Kadowaki M. IgE-induced degranulation of mucosal mast cells is negatively regulated via nicotinic acetylcholine receptors. Biochem Biophys Res Commun. 2008;377(1):321-5.

52. Rivera J, Gilfillan AM. Molecular regulation of mast cell activation. J Allergy Clin Immunol. 2006;117(6):1214-25; quiz 1226.

53. Vig M, Kinet JP. The long and arduous road to CRAC. Cell Calcium. 2007;42(2):157-62.

54. Druey KM. Regulation of G-protein-coupled signaling pathways in allergic inflammation. Immunol Res. 2009;43(1-3):62-76.

55. Karra L, Berent-Maoz B, Ben-Zimra M, Levi-Schaffer F. Are we ready to downregulate mast cells? Curr Opin Immunol. 2009;21(6):708-14.

56. Ravetch JV, Lanier LL. Immune inhibitory receptors. Science. 2000;290(5489):84-9.

57. Kuehn HS, Gilfillan AM. G protein-coupled receptors and the modification of FcepsilonRI-mediated mast cell activation. Immunol Lett. 2007;113(2):59-69.